ATE337299T1 - Aminopyridinyl-, aminoguanidinyl- und alkoxyguanidinyl- substituierte phenylacetamide als protease inhibitoren - Google Patents
Aminopyridinyl-, aminoguanidinyl- und alkoxyguanidinyl- substituierte phenylacetamide als protease inhibitorenInfo
- Publication number
- ATE337299T1 ATE337299T1 AT01979513T AT01979513T ATE337299T1 AT E337299 T1 ATE337299 T1 AT E337299T1 AT 01979513 T AT01979513 T AT 01979513T AT 01979513 T AT01979513 T AT 01979513T AT E337299 T1 ATE337299 T1 AT E337299T1
- Authority
- AT
- Austria
- Prior art keywords
- blood
- sup
- compounds
- inhibiting
- formation
- Prior art date
Links
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 title 2
- -1 AMINOPYRIDINYL Chemical class 0.000 title 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 abstract 5
- 239000008280 blood Substances 0.000 abstract 5
- 230000002401 inhibitory effect Effects 0.000 abstract 5
- 230000015572 biosynthetic process Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 210000001772 blood platelet Anatomy 0.000 abstract 2
- 208000005189 Embolism Diseases 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical class CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 238000011503 in vivo imaging Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
- 108010036927 trypsin-like serine protease Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23813200P | 2000-10-06 | 2000-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE337299T1 true ATE337299T1 (de) | 2006-09-15 |
Family
ID=22896640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01979513T ATE337299T1 (de) | 2000-10-06 | 2001-10-05 | Aminopyridinyl-, aminoguanidinyl- und alkoxyguanidinyl- substituierte phenylacetamide als protease inhibitoren |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US6521663B2 (de) |
| EP (1) | EP1324981B1 (de) |
| JP (1) | JP4256160B2 (de) |
| KR (1) | KR20030045103A (de) |
| CN (1) | CN1315803C (de) |
| AT (1) | ATE337299T1 (de) |
| AU (2) | AU1146402A (de) |
| BR (1) | BR0114263A (de) |
| CA (1) | CA2423883A1 (de) |
| CY (1) | CY1106243T1 (de) |
| DE (1) | DE60122546T2 (de) |
| DK (1) | DK1324981T3 (de) |
| ES (1) | ES2269474T3 (de) |
| HK (1) | HK1058032A1 (de) |
| HR (1) | HRP20030252A2 (de) |
| HU (1) | HUP0303149A3 (de) |
| IL (1) | IL155160A0 (de) |
| MX (1) | MXPA03002998A (de) |
| NO (1) | NO20031390L (de) |
| NZ (1) | NZ525438A (de) |
| PL (1) | PL361185A1 (de) |
| PT (1) | PT1324981E (de) |
| RU (1) | RU2003113205A (de) |
| UA (1) | UA75093C2 (de) |
| WO (1) | WO2002028825A2 (de) |
| ZA (1) | ZA200303091B (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75093C2 (en) * | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
| US6610701B2 (en) * | 2001-02-09 | 2003-08-26 | Merck & Co., Inc. | Thrombin inhibitors |
| US6984645B2 (en) * | 2001-11-16 | 2006-01-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| US7759513B2 (en) * | 2003-02-21 | 2010-07-20 | Nigu Chemie Gmbh | Photolabile protective groups for improved processes to prepare oligonucleotide arrays |
| JP2006522809A (ja) | 2003-04-10 | 2006-10-05 | ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド | 置換フェニルアセトアミおよびプロテアーゼインヒビターとしてのその使用 |
| US7790724B2 (en) | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
| EP1631560A2 (de) | 2003-04-25 | 2006-03-08 | 3-Dimensional Pharmaceuticals, Inc. | C-fms-kinaseinhibitoren |
| US7427683B2 (en) | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
| US7914705B2 (en) * | 2005-01-10 | 2011-03-29 | Robert Eliot Sisson | Flowable electrical conductive liquid |
| HU0500126D0 (en) * | 2005-01-26 | 2005-04-28 | Sanofi Aventis | New compounds and process for their preparation |
| UY29600A1 (es) * | 2005-06-17 | 2007-01-31 | Astrazeneca Ab | Nuevos heterociclos como inhibidores de trombina, composiciones farmacéuticas que los contienen, procedimientos para su preparación y aplicaciones |
| EP2010493B1 (de) | 2006-04-12 | 2016-01-27 | Merck Sharp & Dohme Corp. | Calciumkanal-antagonisten vom typ pyridylamid t |
| RU2354647C2 (ru) * | 2007-06-28 | 2009-05-10 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе |
| RU2353619C2 (ru) * | 2007-06-28 | 2009-04-27 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции |
| CN101665465B (zh) * | 2007-09-19 | 2011-09-07 | 复旦大学 | 一种含胍基杂环化合物凝血酶抑制剂及其制备方法 |
| JP5524071B2 (ja) * | 2007-10-24 | 2014-06-18 | メルク・シャープ・アンド・ドーム・コーポレーション | 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト |
| ES2572502T3 (es) * | 2010-12-02 | 2016-05-31 | Becton Dickinson Co | Dispositivos de recogida de sangre que contienen un agente de estabilización de la sangre |
| CN104857005B (zh) | 2010-12-31 | 2019-04-26 | 阿斯利康公司 | 精氨酸酶抑制剂及其使用方法 |
| CA2835434A1 (en) | 2011-05-17 | 2012-11-22 | Velico Medical, Inc. | Improved platelet storage using a sialidase inhibitor |
| US9788539B2 (en) | 2011-05-17 | 2017-10-17 | Velico Medical, Inc. | Platelet protection solution having beta-galactosidase and sialidase inhibitors |
| CA2887083A1 (en) | 2012-10-05 | 2014-04-10 | Velico Medical, Inc. | Platelet additive solution having a beta-galactosidase inhibitor |
| RU2524647C1 (ru) * | 2012-12-25 | 2014-07-27 | Государственное Бюджетное Учреждение Санкт-Петербургский Научно-Исследовательский Институт Скорой Помощи Им. И.И. Джанелидзе" | Способ лечения синдрома эндогенной интоксикации, обусловленного гиперпротеолизом |
| WO2014120886A1 (en) | 2013-01-30 | 2014-08-07 | Velico Medical, Inc. | Platelet additive solution having a self-assembling hydrogel-forming peptide |
| WO2015143376A1 (en) * | 2014-03-21 | 2015-09-24 | Nivalis Therapeutics, Inc. | Novel compounds for the treatment of cystic fibrosis |
| IL286788B2 (en) * | 2015-07-21 | 2024-01-01 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| US12173350B2 (en) * | 2017-05-24 | 2024-12-24 | Ramot At Tel-Aviv University Ltd. | Chemiluminescent probes for imaging/detection of proteases |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084466A (en) | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
| CA2075154A1 (en) * | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
| DE4208051A1 (de) | 1992-03-13 | 1993-09-16 | Bayer Ag | Substituierte phenylessigsaeureamide |
| DE4319887A1 (de) | 1993-06-16 | 1994-12-22 | Hoechst Schering Agrevo Gmbh | Arylacetamide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Fungizide |
| EP0713483B1 (de) | 1993-08-12 | 2003-01-15 | AstraZeneca AB | Amidin-derivate mit stickstoffoxid-synthease-aktivität |
| US5885967A (en) | 1994-03-04 | 1999-03-23 | Eli Lilly And Company | Antithrombotic agents |
| JPH0892224A (ja) | 1994-09-16 | 1996-04-09 | Kumiai Chem Ind Co Ltd | ３，５−置換フェニルトリアゾール誘導体および殺虫、殺ダニ剤 |
| JP3570752B2 (ja) | 1994-09-22 | 2004-09-29 | 三井化学株式会社 | ４−置換カルボニルクマリン誘導体、およびこれを用いた可視光感光性組成物 |
| DE19507822B4 (de) | 1995-02-21 | 2006-07-20 | Schering Ag | Substituierte DTPA-Monoamide der zentralen Carbonsäure und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel |
| US5741819A (en) * | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| US5721214A (en) | 1995-06-07 | 1998-02-24 | Cor Therapeutics, Inc. | Inhibitors of factor Xa |
| WO1997001338A1 (en) * | 1995-06-27 | 1997-01-16 | Merck & Co., Inc. | Pyridinone-thrombin inhibitors |
| HUP9802764A3 (en) | 1995-09-29 | 2000-03-28 | Dimensional Pharm Inc | Guanidino protease inhibitors |
| WO1997030971A1 (en) | 1996-02-22 | 1997-08-28 | The Du Pont Merck Pharmaceutical Company | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS |
| DE19615262A1 (de) | 1996-04-18 | 1997-10-23 | Bayer Ag | Heteroverknüpfte Phenylglycinolamide |
| AU3496297A (en) | 1996-06-25 | 1998-01-14 | Eli Lilly And Company | Anticoagulant agents |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| DE19642863A1 (de) | 1996-10-17 | 1998-04-23 | Bayer Ag | Amide |
| TW499412B (en) | 1996-11-26 | 2002-08-21 | Dimensional Pharm Inc | Aminoguanidines and alkoxyguanidines as protease inhibitors |
| GB9703201D0 (en) | 1997-02-15 | 1997-04-02 | Zeneca Ltd | Chemical compounds |
| JP4346113B2 (ja) | 1997-02-21 | 2009-10-21 | バイエル・アクチエンゲゼルシヤフト | アリールスルホンアミド及びそれらの類似体並びに神経変性疾患の治療におけるそれらの使用 |
| US6049006A (en) | 1997-06-16 | 2000-04-11 | American Home Products Corp. | Elevation of HDL cholesterol by N-[2-[(aminothioxomethyl) hydrazono]-2-arylethyl]amides |
| US6034272A (en) | 1997-06-16 | 2000-03-07 | American Home Products Corporation | Elevation of HDL cholesterol by N-[4-[(aminothioxomethyl) hydrazono]-4-arylbutyl]amides |
| WO1998057926A1 (en) | 1997-06-16 | 1998-12-23 | American Home Products Corporation | Elevation of hdl cholesterol by n-[2-[ (aminothioxomethyl)hydrazono] -2-arylethyl]amides |
| AU7691298A (en) | 1997-06-16 | 1999-01-04 | American Home Products Corporation | Elevation of hdl cholesterol by n-{4-{ (aminothioxomethyl) hydrazono} -4-arylbutyl}amides |
| ATE344246T1 (de) * | 1997-11-26 | 2006-11-15 | Ortho Mcneil Pharm Inc | Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer |
| CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
| US6344486B1 (en) * | 1998-04-03 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| AU3459999A (en) | 1998-04-27 | 1999-11-16 | Warner-Lambert Company | Substituted diarylalkyl amides as calcium channel antagonists |
| DE19824470A1 (de) | 1998-05-30 | 1999-12-02 | Boehringer Ingelheim Pharma | Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| DE19937494A1 (de) * | 1999-08-07 | 2001-02-08 | Boehringer Ingelheim Pharma | Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2001068605A1 (en) | 2000-03-13 | 2001-09-20 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
| UA75093C2 (en) * | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
-
2001
- 2001-05-10 UA UA2003054058A patent/UA75093C2/uk unknown
- 2001-10-05 KR KR10-2003-7004831A patent/KR20030045103A/ko not_active Ceased
- 2001-10-05 AU AU1146402A patent/AU1146402A/xx active Pending
- 2001-10-05 HU HU0303149A patent/HUP0303149A3/hu unknown
- 2001-10-05 HK HK0100042A patent/HK1058032A1/en not_active IP Right Cessation
- 2001-10-05 RU RU2003113205/04A patent/RU2003113205A/ru not_active Application Discontinuation
- 2001-10-05 MX MXPA03002998A patent/MXPA03002998A/es active IP Right Grant
- 2001-10-05 PT PT01979513T patent/PT1324981E/pt unknown
- 2001-10-05 PL PL36118501A patent/PL361185A1/xx not_active Application Discontinuation
- 2001-10-05 DK DK01979513T patent/DK1324981T3/da active
- 2001-10-05 AT AT01979513T patent/ATE337299T1/de not_active IP Right Cessation
- 2001-10-05 ES ES01979513T patent/ES2269474T3/es not_active Expired - Lifetime
- 2001-10-05 JP JP2002532411A patent/JP4256160B2/ja not_active Expired - Fee Related
- 2001-10-05 WO PCT/US2001/031249 patent/WO2002028825A2/en not_active Ceased
- 2001-10-05 AU AU2002211464A patent/AU2002211464B2/en not_active Ceased
- 2001-10-05 ZA ZA200303091A patent/ZA200303091B/en unknown
- 2001-10-05 DE DE60122546T patent/DE60122546T2/de not_active Expired - Fee Related
- 2001-10-05 BR BR0114263-1A patent/BR0114263A/pt not_active IP Right Cessation
- 2001-10-05 CN CNB018182542A patent/CN1315803C/zh not_active Expired - Fee Related
- 2001-10-05 EP EP01979513A patent/EP1324981B1/de not_active Expired - Lifetime
- 2001-10-05 US US09/971,000 patent/US6521663B2/en not_active Expired - Lifetime
- 2001-10-05 CA CA002423883A patent/CA2423883A1/en not_active Abandoned
- 2001-10-05 NZ NZ525438A patent/NZ525438A/en unknown
- 2001-10-05 IL IL15516001A patent/IL155160A0/xx unknown
- 2001-10-05 HR HR20030252A patent/HRP20030252A2/hr not_active Application Discontinuation
-
2002
- 2002-10-03 US US10/262,871 patent/US6900231B2/en not_active Expired - Lifetime
-
2003
- 2003-03-26 NO NO20031390A patent/NO20031390L/no not_active Application Discontinuation
-
2005
- 2005-01-10 US US11/032,297 patent/US20050159457A1/en not_active Abandoned
-
2006
- 2006-11-14 CY CY20061101657T patent/CY1106243T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE337299T1 (de) | Aminopyridinyl-, aminoguanidinyl- und alkoxyguanidinyl- substituierte phenylacetamide als protease inhibitoren | |
| DK1086122T3 (da) | Pyrazinonproteaseinhibitorer | |
| BR9815325A (pt) | Heteroaril, aminoguanidinas e alcóxiguanidinas eseu uso como inibidores da protease | |
| WO1998023565A3 (en) | Aminoguanidines and alkoxyguanidines as protease inhibitors | |
| ATE270269T1 (de) | Boenzoesäureamid und -sulfonamid substituierte aminoguanidine und alkoxyguanidine als proteaseinhibitoren | |
| ATE338030T1 (de) | Amidine-inhibitoren der serine-proteasen | |
| DE60040345D1 (de) | VERFAHREN ZUR HERSTELLUNG EINER REVERSIBEL INAKTIVEN, ANGESäUERTEN PLASMINZUSAMMENSETZUNG | |
| WO2002006248A3 (en) | Cyclic oxyguanidine pyrazinones as protease inhibitors | |
| TW200508200A (en) | Substituted phenyl acetamides and their use as protease inhibitors | |
| ATE250056T1 (de) | Heteroaryl protease inhibitoren und diagnostische bilderzeugungsmittel | |
| MXPA03000963A (es) | Inhibidores de oxiguanidina ciclica proteasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1324981 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |